Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

by · The Markets Daily

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the transaction, the chief financial officer directly owned 153,503 shares in the company, valued at approximately $18,727,366. The trade was a 1.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $121.36 on Thursday. The company’s fifty day simple moving average is $122.12 and its two-hundred day simple moving average is $115.97. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The firm has a market cap of $150.57 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds have recently bought and sold shares of the business. Activest Wealth Management lifted its holdings in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. GoalVest Advisory LLC increased its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences during the third quarter valued at $26,000. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences in the second quarter worth $27,000. Finally, Putney Financial Group LLC grew its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on GILD. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. HSBC lifted their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Finally, TD Cowen lifted their price objective on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.54.

Get Our Latest Analysis on Gilead Sciences

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More